Attached files
| file | filename |
|---|---|
| EX-10.20 - EXHIBIT 10.20 - TG THERAPEUTICS, INC. | tgtx_ex1020.htm |
| EX-32.2 - EXHIBIT 32.2 - TG THERAPEUTICS, INC. | tgtx_ex322.htm |
| EX-31.2 - EXHIBIT 31.2 - TG THERAPEUTICS, INC. | tgtx_ex312.htm |
| EX-31.1 - EXHIBIT 31.1 - TG THERAPEUTICS, INC. | tgtx_ex311.htm |
| EX-23.1 - EXHIBIT 23.1 - TG THERAPEUTICS, INC. | tgtx_ex231.htm |
| EX-21.1 - EXHIBIT 21.1 - TG THERAPEUTICS, INC. | tgtx_ex211.htm |
| 10-K - 10-K - TG THERAPEUTICS, INC. | v031418_10K.htm |
Exhibit 32.1
STATEMENT OF CHIEF EXECUTIVE OFFICER
OF
TG THERAPEUTICS, INC.
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
TG THERAPEUTICS, INC.
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with
the annual report of TG Therapeutics, Inc. (the
“Company”) on Form 10-K for the year ended December 31,
2017 as filed with the Securities and Exchange Commission (the
“Report”), I, Michael S. Weiss, Executive Chairman,
Chief Executive Officer and President of the Company, certify,
pursuant to 18 U.S.C. §1350, as adopted pursuant to §906
of the Sarbanes-Oxley Act of 2002, that, based on my
knowledge:
1) The Report fully
complies with the requirements of Section 13(a) or 15(d) of the
Securities Exchange Act of 1934, as amended;
and
2) The information contained
in the Report fairly presents, in all material respects, the
financial condition and results of operations of the
Company.
|
Date: March 15,
2018
|
|
/s/ Michael S.
Weiss
|
|
|
Michael S.
Weiss
Executive Chairman, Chief Executive Officer and President Principal Executive Officer |
|